Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.

about

Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.

Item

http://www.wikidata.org/entity/Q54774472

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Fracture after androgen depriv ...... isk of skeletal complications.

@en

Fracture after androgen depriv ...... isk of skeletal complications.

@nl

type

Item

label

Fracture after androgen depriv ...... isk of skeletal complications.

@en

Fracture after androgen depriv ...... isk of skeletal complications.

@nl

prefLabel

Fracture after androgen depriv ...... isk of skeletal complications.

@en

Fracture after androgen depriv ...... isk of skeletal complications.

@nl

P1476

Fracture after androgen depriv ...... isk of skeletal complications.

@en

P2093

Fay H Cafferty

http://www.w3.org/2001/XMLSchema#string

Paul D Abel

http://www.w3.org/2001/XMLSchema#string

Richard L Abel

http://www.w3.org/2001/XMLSchema#string

Ruth E Langley

http://www.w3.org/2001/XMLSchema#string

Syed Imran Ali Shah

http://www.w3.org/2001/XMLSchema#string

P2860

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5

Regulation of adult bone turnover by sex steroids

Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer.

Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism.

Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).

Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.

Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate.

Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer.

P304

E431-2

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJU.12375

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263111304

http://www.w3.org/2001/XMLSchema#string

P698

24118960

http://www.w3.org/2001/XMLSchema#string